EXEL Exelixis, Inc. Stock Quote

EXEL [NASD]

Index	-	P/E	33.45	EPS (ttm)	0.51	Insider Own	1.60%	Shs Outstand	315.38M	Perf Week	-2.46%
Market Cap	5.24B	Forward P/E	22.93	EPS next Y	0.74	Insider Trans	-7.49%	Shs Float	309.61M	Perf Month	-19.91%
Income	164.30M	PEG	0.73	EPS next Q	0.16	Inst Own	85.40%	Short Float	3.62%	Perf Quarter	-12.20%
Sales	1.25B	P/S	4.18	EPS this Y	-65.50%	Inst Trans	-0.91%	Short Ratio	6.22	Perf Half Y	-24.35%
Book/sh	6.70	P/B	2.55	EPS next Y	48.50%	ROA	7.20%	Target Price	29.77	Perf Year	-8.92%
Cash/sh	4.57	P/C	3.73	EPS next 5Y	46.00%	ROE	8.30%	52W Range	16.19 - 25.77	Perf YTD	-15.00%
Dividend	-	P/FCF	19.04	EPS past 5Y	19.70%	ROI	4.80%	52W High	-33.26%	Beta	0.81
Dividend %	-	Quick Ratio	6.10	Sales past 5Y	92.70%	Gross Margin	96.10%	52W Low	6.24%	ATR	0.58
Employees	773	Current Ratio	6.20	Sales Q/Q	42.10%	Oper. Margin	15.50%	RSI (14)	32.56	Volatility	3.12% 3.26%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	214.50%	Profit Margin	13.10%	Rel Volume	0.88	Prev Close	17.06
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 02 AMC	Payout	0.00%	Avg Volume	1.80M	Price	17.20
Recom	2.00	SMA20	-7.69%	SMA50	-14.59%	SMA200	-18.09%	Volume	683,800	Change	0.82%

Nov-19-21

Initiated

Piper Sandler

Overweight

$34

Nov-03-21

Resumed

Jefferies

Buy

$28

Oct-07-21

Initiated

Jefferies

Buy

$28

Aug-06-21

Reiterated

H.C. Wainwright

Buy

$35 → $64

Jun-15-21

Initiated

H.C. Wainwright

Buy

$47

May-18-21

Resumed

Goldman

Sell

$23

Mar-31-21

Initiated

Credit Suisse

Outperform

$30

Mar-12-21

Initiated

Wolfe Research

Outperform

$35

Mar-04-20

Initiated

Barclays

Overweight

$26

Jan-13-20

Initiated

SunTrust

Buy

$31

Nov-13-19

Initiated

BofA/Merrill

Buy

$22

Mar-18-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Sep-17-18

Initiated

Goldman

Neutral

$22

Sep-10-18

Initiated

Morgan Stanley

Underweight

$19

May-11-18

Reiterated

Needham

Buy

$33 → $30

Oct-17-17

Reiterated

RBC Capital Mkts

Outperform

$33 → $39

Oct-17-17

Reiterated

Needham

Buy

$30 → $33

Oct-16-17

Reiterated

SunTrust

Buy

$32 → $35

Sep-22-17

Downgrade

Leerink Partners

Outperform → Mkt Perform

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$32

Nov-20-21 06:00AM	Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021 Business Wire
Nov-18-21 10:27AM	Notable Exelixis Insider Trades $2.3M In Company Stock Benzinga
Nov-12-21 05:51AM	The Smartest Stocks to Buy With $20 Right Now Motley Fool
Nov-09-21 08:00AM	Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer Business Wire
Nov-04-21 11:21AM	EVP And General Counsel Of Exelixis Sold $110K In Stock Benzinga
09:25AM	Is Exelixis, Inc.'s (NASDAQ:EXEL) Recent Stock Performance Influenced By Its Fundamentals In Any Way? Simply Wall St.
06:05AM	3 No-Brainer Biotech Stocks to Buy in November Motley Fool
Nov-03-21 04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December Business Wire -12.07%
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) Zacks
11:40AM	EXEL vs. ILMN: Which Stock Is the Better Value Option? Zacks
08:56AM	Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View Zacks
Nov-02-21 11:01PM	Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript Motley Fool
06:25PM	Exelixis (EXEL) Q3 Earnings and Revenues Lag Estimates Zacks
04:05PM	Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update Business Wire
Nov-01-21 10:54AM	Is a Surprise Coming for Exelixis (EXEL) This Earnings Season? Zacks
Oct-30-21 06:00AM	3 Biotech Stocks That Could Make You Richer Motley Fool
Oct-29-21 08:50AM	This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar Zacks
Oct-28-21 10:00AM	Down 76%: Is Cortexyme Stock a Bargain? Motley Fool
Oct-26-21 03:02PM	Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? Zacks
10:43AM	Wall Street Analysts Predict a 52% Upside in Exelixis (EXEL): Here's What You Should Know Zacks
10:39AM	New Strong Buy Stocks for October 26th Zacks
Oct-19-21 04:05PM	Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021 Business Wire
10:00AM	Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? Zacks
Oct-18-21 12:21PM	Should I Buy Exelixis, Inc. (EXEL)? Insider Monkey
Oct-14-21 10:02AM	Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx Zacks
08:00AM	Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkins Lymphoma Business Wire
08:00AM	Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes Business Wire
Oct-13-21 05:51AM	4 Growth Stocks With 187% to 434% Upside, According to Wall Street Motley Fool
Sep-28-21 05:51AM	Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter Motley Fool
Sep-22-21 08:36AM	Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA Zacks
Sep-20-21 11:57AM	Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer Zacks
11:30AM	Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021 Business Wire
09:51AM	The 3.8% return this week takes Exelixis' (NASDAQ:EXEL) shareholders five-year gains to 39% Simply Wall St.
Sep-18-21 07:30AM	Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021 Business Wire
Sep-17-21 04:23PM	Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Business Wire
Sep-16-21 07:49AM	Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery Benzinga
02:30AM	Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021 Business Wire
Sep-11-21 11:45AM	2 Top Biotech Stocks to Buy Right Now Motley Fool
Sep-06-21 01:00PM	Exelixis Statement on the Passing of Two Senior Executives Business Wire
Sep-02-21 06:19AM	Is Exelixis Stock a Buy? Motley Fool
Sep-01-21 04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September Business Wire
Aug-26-21 07:51AM	Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer Benzinga
05:51AM	4 Growth Stocks With 116% to 247% Upside, According to Wall Street Motley Fool
Aug-25-21 04:05PM	Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma Business Wire
Aug-20-21 09:11AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio Zacks
Aug-18-21 11:47AM	Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations Zacks
Aug-17-21 08:37AM	Exelixis (EXEL) Expands Oncology Collaboration With Invenra Zacks
Aug-16-21 03:47PM	Exelixis, Invenra Expand Oncology Pact Benzinga
08:05AM	Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology Business Wire
Aug-06-21 11:29AM	Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View Zacks
09:13AM	News Flash: Analysts Just Made A Substantial Upgrade To Their Exelixis, Inc. (NASDAQ:EXEL) Forecasts Simply Wall St.
12:01AM	Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 07:15PM	Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates Zacks
04:05PM	Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update Business Wire
08:00AM	Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Business Wire
Aug-02-21 05:51AM	3 Top Stocks That'll Make You Richer in August (and Beyond) Motley Fool
Jul-29-21 03:05PM	Earnings Preview: Exelixis (EXEL) Q2 Earnings Expected to Decline Zacks
Jul-26-21 05:51AM	5 No-Brainer Stocks to Invest $500 In Right Now Motley Fool
Jul-22-21 04:05PM	Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 Business Wire
08:06AM	4 Biotech Stocks That Could Be Bargains Barrons.com
Jul-19-21 02:45AM	Do Institutions Own Exelixis, Inc. (NASDAQ:EXEL) Shares? Simply Wall St.
Jul-16-21 05:51AM	The Smartest Stocks to Buy With $20 in July Motley Fool
Jul-13-21 10:10AM	Hedge Funds Are Buying Exelixis, Inc. (EXEL) Insider Monkey
Jul-09-21 07:41AM	After Plummeting More Than 23%, Is Exelixis a Buy? Motley Fool
06:55AM	Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results? Motley Fool
Jul-08-21 04:05PM	Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021 Business Wire
Jul-02-21 05:51AM	The Smartest Stocks to Buy With $100 for the Second Half of 2021 Motley Fool
Jun-30-21 04:04PM	Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More Zacks
Jun-29-21 07:03PM	Exelixis (EXEL) Down on Data From Ongoing Liver Cancer Study Zacks
Jun-28-21 04:15PM	Exelixis Stock Collapses; Can It Recover From Mixed Results In Liver Cancer Study? Investor's Business Daily -23.06%
12:04PM	Here's Why Exelixis Stock Is Dropping Today Motley Fool
01:00AM	Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer Business Wire
Jun-18-21 08:00AM	Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence Business Wire
05:51AM	The Smartest Stocks to Buy With $100 Right Now Motley Fool
Jun-15-21 11:39AM	Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers Zacks
Jun-14-21 08:00AM	Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors Business Wire
Jun-07-21 08:00AM	Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021 Business Wire
Jun-06-21 10:06AM	Here's What Crushed Exelixis' Earnings Motley Fool
Jun-04-21 09:00AM	Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma Business Wire
09:00AM	Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021 Business Wire
09:00AM	Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire
May-30-21 06:00AM	2 Top Biotech Stocks to Buy Right Now Motley Fool
May-26-21 04:15PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June Business Wire
06:06AM	The Best Stocks to Invest $3,000 in Right Now Motley Fool
May-25-21 10:51AM	Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study Zacks -5.57%
07:48AM	Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients Benzinga
May-24-21 04:05PM	Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Business Wire
May-22-21 06:30AM	Is Exelixis a Buy? Motley Fool
May-21-21 06:31AM	What Investors Should Look for With Exelixis, DermTech, and Teladoc Health Motley Fool
May-20-21 01:35AM	Here's Why We Think Exelixis, Inc.'s (NASDAQ:EXEL) CEO Compensation Looks Fair Simply Wall St.
May-09-21 02:06PM	Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma? Motley Fool
May-07-21 01:04PM	Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat Zacks +8.14%
11:30AM	Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript Motley Fool
05:51AM	The Smartest Stocks to Buy With $50 Right Now Motley Fool
May-06-21 07:05PM	Exelixis (EXEL) Reports Break-Even Earnings for Q1 Zacks
04:05PM	Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update Business Wire
03:15PM	Exelixis, Inc. to Host Earnings Call ACCESSWIRE
May-04-21 08:00AM	Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharmas First-in-Class Humanized Antibody Program Against a Novel Oncology Target Business Wire
Apr-27-21 04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May Business Wire
Apr-26-21 09:29AM	Is EXEL Stock A Buy or Sell? Insider Monkey

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haley Patrick J.	EVP, Commercial	Nov 24	Sale	17.25	17,236	297,321	237,802	Nov 26 07:39 PM
FELDBAUM CARL B	Director	Nov 19	Option Exercise	3.13	20,000	62,600	28,521	Nov 23 08:11 PM
FELDBAUM CARL B	Director	Nov 19	Sale	17.62	20,000	352,400	8,521	Nov 23 08:11 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Nov 15	Option Exercise	6.21	47,500	294,975	458,740	Nov 17 08:02 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Nov 15	Sale	18.09	47,500	859,275	411,240	Nov 17 08:02 PM
Hessekiel Jeffrey	EVP and General Counsel	Nov 01	Sale	22.03	5,117	112,728	632,825	Nov 03 08:12 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Oct 15	Option Exercise	6.21	47,500	294,975	458,740	Oct 15 08:15 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Oct 15	Sale	21.92	47,500	1,041,200	411,240	Oct 15 08:15 PM
Hessekiel Jeffrey	EVP and General Counsel	Oct 15	Sale	22.02	12,883	283,684	637,942	Oct 15 08:14 PM
Senner Christopher J.	EVP and CFO	Sep 21	Option Exercise	3.66	90,000	329,400	446,591	Sep 23 08:16 PM
Haley Patrick J.	EVP, Commercial	Sep 16	Option Exercise	1.70	25,000	42,500	305,994	Sep 17 07:58 PM
Haley Patrick J.	EVP, Commercial	Sep 16	Sale	20.36	25,000	509,000	280,994	Sep 17 07:58 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Sep 15	Option Exercise	6.21	47,500	294,975	436,967	Sep 17 07:56 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Sep 15	Sale	20.46	47,500	971,850	389,467	Sep 17 07:56 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Aug 16	Option Exercise	1.90	55,000	104,500	444,467	Aug 18 07:56 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Aug 16	Sale	18.44	55,000	1,014,200	389,467	Aug 18 07:56 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Jul 26	Option Exercise	4.20	40,000	168,000	689,078	Jul 28 08:06 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Jul 21	Option Exercise	4.20	35,000	147,000	649,078	Jul 23 07:47 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jul 15	Option Exercise	1.90	60,000	114,000	449,467	Jul 16 07:58 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jul 15	Sale	17.47	60,000	1,048,200	389,467	Jul 16 07:58 PM
COHEN CHARLES	Director	Jul 06	Option Exercise	4.71	80,000	377,200	261,375	Jul 08 07:45 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jun 17	Option Exercise	1.90	60,000	114,000	449,467	Jun 22 08:03 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jun 17	Sale	22.18	60,000	1,330,800	389,467	Jun 22 08:03 PM
Haley Patrick J.	EVP, Commercial	May 18	Sale	24.73	14,593	360,885	280,994	May 18 08:13 PM
MARCHESI VINCENT T	Director	May 14	Option Exercise	6.30	40,000	252,000	106,115	May 17 08:13 PM
MARCHESI VINCENT T	Director	May 14	Sale	25.04	40,000	1,001,600	66,115	May 17 08:13 PM
POSTE GEORGE	Director	May 14	Sale	24.97	40,802	1,018,826	157,190	May 17 08:11 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	May 13	Option Exercise	1.90	100,000	190,000	714,078	May 14 08:35 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	May 13	Sale	25.38	100,000	2,538,000	614,078	May 14 08:35 PM
MORRISSEY MICHAEL	President and CEO	May 12	Option Exercise	4.20	50,000	210,000	541,813	May 14 08:51 PM
PAPADOPOULOS STELIOS	Director	May 11	Option Exercise	4.27	120,000	512,400	1,293,600	May 13 08:32 PM
PAPADOPOULOS STELIOS	Director	May 11	Sale	24.98	20,770	518,794	1,218,675	May 13 08:32 PM
Freire Maria C	Director	May 11	Sale	25.01	8,275	206,958	31,827	May 17 08:15 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 26	Option Exercise	1.70	50,000	85,000	663,482	Apr 28 08:10 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 26	Sale	25.00	50,000	1,250,000	613,482	Apr 28 08:10 PM
Haley Patrick J.	EVP, Commercial	Apr 26	Sale	25.03	7,665	191,855	297,392	Apr 28 08:08 PM
Hessekiel Jeffrey	EVP and General Counsel	Apr 26	Sale	25.03	18,000	450,540	628,248	Apr 28 08:06 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 01	Option Exercise	1.70	50,000	85,000	663,482	Apr 02 07:41 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Apr 01	Option Exercise	1.70	60,000	102,000	449,467	Apr 02 07:51 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Apr 01	Sale	22.96	60,000	1,377,600	389,467	Apr 02 07:51 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 01	Sale	23.00	50,000	1,150,000	613,482	Apr 02 07:41 PM
WYSZOMIERSKI JACK L	Director	Mar 29	Option Exercise	3.38	40,000	135,200	237,809	Mar 31 09:02 PM
WYSZOMIERSKI JACK L	Director	Mar 29	Sale	22.64	6,220	140,821	231,589	Mar 31 09:02 PM
Garber Alan M	Director	Mar 15	Option Exercise	3.38	40,000	135,200	52,718	Mar 17 08:11 PM
Garber Alan M	Director	Mar 15	Sale	23.60	40,000	944,000	12,718	Mar 17 08:11 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Mar 01	Option Exercise	1.70	65,000	110,500	405,072	Mar 03 07:49 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Mar 01	Sale	22.11	65,000	1,437,150	340,072	Mar 03 07:49 PM
COHEN CHARLES	Director	Feb 24	Option Exercise	3.38	40,000	135,200	221,375	Feb 26 08:10 PM
COHEN CHARLES	Director	Feb 24	Sale	22.69	40,000	907,600	181,375	Feb 26 08:10 PM
WILLSEY LANCE	Director	Feb 23	Option Exercise	3.38	40,000	135,200	464,415	Feb 24 08:11 PM
WILLSEY LANCE	Director	Feb 23	Sale	21.93	40,000	877,136	424,415	Feb 24 08:11 PM
POSTE GEORGE	Director	Feb 22	Option Exercise	3.38	40,000	135,200	197,992	Feb 24 08:18 PM
MARCHESI VINCENT T	Director	Feb 22	Sale	22.29	24,097	537,122	66,115	Feb 24 08:15 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 18	Option Exercise	1.70	50,000	85,000	590,597	Feb 19 07:57 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 18	Sale	22.35	50,000	1,117,500	540,597	Feb 19 07:57 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 17	Option Exercise	1.70	50,000	85,000	590,597	Feb 19 07:57 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 17	Sale	22.50	50,000	1,125,000	540,597	Feb 19 07:57 PM
FELDBAUM CARL B	Director	Feb 16	Option Exercise	3.38	20,000	67,600	28,521	Feb 17 08:03 PM
FELDBAUM CARL B	Director	Feb 16	Sale	21.96	20,000	439,200	8,521	Feb 17 08:03 PM
WILLSEY LANCE	Director	Feb 16	Sale	21.90	50,000	1,095,000	424,415	Feb 24 08:11 PM
Haley Patrick J.	EVP, Commercial	Feb 12	Sale	21.57	45,000	970,650	246,887	Feb 17 08:15 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Feb 01	Option Exercise	1.70	65,000	110,500	348,124	Feb 03 07:57 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Feb 01	Sale	22.08	65,000	1,435,200	283,124	Feb 03 07:57 PM
Senner Christopher J.	EVP and CFO	Jan 12	Option Exercise	3.66	30,000	109,800	275,596	Jan 14 08:22 PM
Senner Christopher J.	EVP and CFO	Jan 12	Sale	25.00	30,000	750,000	245,596	Jan 14 08:22 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jan 04	Option Exercise	1.70	65,000	110,500	348,124	Jan 06 08:40 PM
Hessekiel Jeffrey	EVP and General Counsel	Jan 04	Option Exercise	5.12	50,000	256,100	541,754	Jan 06 08:22 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jan 04	Sale	20.32	65,000	1,320,800	283,124	Jan 06 08:40 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Dec 18	Option Exercise	1.70	65,000	110,500	348,124	Dec 22 07:58 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Dec 18	Sale	20.01	65,000	1,300,650	283,124	Dec 22 07:58 PM
WILLSEY LANCE	Director	Dec 04	Option Exercise	5.82	106,142	617,746	474,415	Dec 04 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience